NextCure (2US0) Price & Analysis

0 Followers

2US0 Stock Chart & Stats

€4.73

€0.00(0.00%)

At close: Jul 24 4:00 PM EDT

€4.73

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€4.54 - €4.73

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€22.60M

Enterprise Value-€7.31

Total Cash (Recent Filing)€20.09M

Total Debt (Recent Filing)€4.29M

Price to Earnings (P/E)―

Beta2.47

Next Earnings

Oct 29, 2026

EPS Estimate

-0.77

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.58

Shares Outstanding4,577,359

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)1.15

Price to Sales (P/S)0.00

P/FCF Ratio-0.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€17.41

Price Target Upside268.12% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-5.35

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strategic Funding And Pipeline ExpansionThe proposed combination would provide substantial capital for advancing AVR-001 through multiple clinical milestones, while adding an oral IL-23 program to the listed platform. This materially improves development funding and creates a clearer pipeline path than NextCure’s standalone oncology model.

Operating Cost ReductionExiting the Beltsville lease removes ongoing rental commitments and consolidates the company’s physical footprint. Although the termination required a one-time payment, lower recurring facilities expense can extend available capital and support a more disciplined cost structure over the coming quarters.

Relatively Low LeverageModest debt relative to equity limits interest and refinancing pressure compared with highly levered biotechnology peers. This gives the company greater balance-sheet flexibility while it funds clinical development, even though the shrinking equity base means the benefit is partly offset by broader financial weakness.

Bears Say

No Commercial Revenue And Persistent LossesThe absence of revenue leaves the company dependent on financing, partnerships, or future clinical success rather than operating sales. Continued sizable losses also show that current programs are not yet supporting the cost base, limiting earnings visibility and making profitability dependent on successful development and commercialization.

Sustained Cash ConsumptionPersistent negative operating and free cash flow means the business is not self-funding its research and development activities. Continued cash consumption can require recurring external capital, which may constrain strategic choices and expose shareholders to additional financing-related dilution over the medium term.

Severe Ownership Reset And Strategic TransitionThe merger substantially changes control and leaves existing NextCure holders with only a small residual ownership position, while the company shifts from oncology toward Avere’s inflammation franchise. The workforce reduction and leadership transition further underscore a major reset in strategy and organizational continuity.

NextCure News

NextCure Ends Beltsville Lease to Cut Operating Costs

NextCure ( ($NXTC) ) has issued an announcement. On August 28, 2026, NextCure, Inc. entered into a ninth...

16d ago

NXTC

NextCure reports Q2 EPS ($2.80), consensus ($1.92)

“Following quarter end, we announced our proposed merger with Avere Therapeutics, together with Avere’s concurrent private financing expected...

1M ago

NXTC

NextCure trading resumes

10:41 EDT NextCure (NXTC) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking...

2M ago

NXTC

NextCure trading halted, volatility trading pause

10:36 EDT NextCure (NXTC) trading halted, volatility trading pause Published first on TheFly – the ultimate source for...

2M ago

NXTC

Analyst Initiates Buy on NextCure as Merger with Avere Positions AVR-001 for Well-Financed Late-Stage Development in Psoriasis and UC

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on NextCure today and set a price target of...

2M ago

NXTC

NextCure Announces Transformative All-Stock Merger With Avere

NextCure ( ($NXTC) ) has shared an announcement. On July 14, 2026, NextCure and privately held Avere Therapeutics...

2M ago

NXTC

Midday Fly By: IBM warns on Q2 outlook, Goldman reports sharp beat

Stocks moved higher after softer inflation data shut the door on a Fed rate hike this month. Both...

2M ago

Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That

WSW, NY, July 14th, 2026, FinanceWire Surgical site infections are among the most expensive complications hospitals face. A...

2M ago

LLY

NXTC

Why Is Penny Stock NextCure (NXTC) Up Today?

NextCure stock saw a major rally on Tuesday after the company revealed a merger agreement. ...

2M ago

NXTC

NextCure, Avere Therapeutics enter definitive merger agreement

06:02 EDT NextCure (NXTC), Avere Therapeutics enter definitive merger agreement Published first on TheFly – the ultimate source...

2M ago

NXTC

NextCure, Avere Therapeutics enter definitive merger agreement

NextCure (NXTC) and Avere Therapeutics, a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, announced...

2M ago

NXTC

NextCure Shareholders Approve Expanded Omnibus Incentive Plan

NextCure ( ($NXTC) ) has shared an announcement. On June 18, 2026, NextCure stockholders approved an amendment and...

3M ago

NXTC

NextCure share weakness overdone, says Lucid Capital

Lucid Capital analyst Christopher Liu says NextCure’s (NXTC) SIM0505 data “were relatively encouraging,” despite the shares trading down...

4M ago

NXTC

NextCure presents Phase 1 data for SIM0505 in gynecologic cancers

NextCure (NXTC) and Simcere Zaiming Pharmaceutical announced positive Phase 1 dose escalation data for SIM0505, an antibody-drug conjugate...

4M ago

NXTC

2US0 FAQ

What was NextCure Inc’s price range in the past 12 months?

NextCure Inc lowest stock price was €4.54 and its highest was €4.73 in the past 12 months.

What is NextCure Inc’s market cap?

NextCure Inc’s market cap is €22.60M.

When is NextCure Inc’s upcoming earnings report date?

NextCure Inc’s upcoming earnings report date is Oct 29, 2026 which is in 39 days.

How were NextCure Inc’s earnings last quarter?

NextCure Inc released its earnings results on Aug 06, 2026. The company reported -€2.395 earnings per share for the quarter, missing the consensus estimate of -€1.668 by -€0.727.

Is NextCure Inc overvalued?

According to Wall Street analysts NextCure Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does NextCure Inc pay dividends?

NextCure Inc does not currently pay dividends.

What is NextCure Inc’s EPS estimate?

NextCure Inc’s EPS estimate is -0.77.

How many shares outstanding does NextCure Inc have?

NextCure Inc has 4,577,359 shares outstanding.

What happened to NextCure Inc’s price movement after its last earnings report?

NextCure Inc reported an EPS of -€2.395 in its last earnings report, missing expectations of -€1.668. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of NextCure Inc?

Currently, no hedge funds are holding shares in DE:2US0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCure Inc

NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.

NextCure (2US0) Earnings & Revenues

Historic Earnings Reports

2US0 Stock 12 Month Forecast

Average Price Target

€17.41

▲(268.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","18":"€18","6.75":"€6.75","10.5":"€10.5","14.25":"€14.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.412077800000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€17.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.412077800000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€17.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.412077800000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.75,10.5,14.25,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.727,5.702775215384616,6.678550430769231,7.654325646153847,8.630100861538462,9.605876076923078,10.581651292307694,11.557426507692309,12.533201723076925,13.50897693846154,14.484752153846156,15.460527369230771,16.436302584615387,{"y":17.412077800000002,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.727,5.702775215384616,6.678550430769231,7.654325646153847,8.630100861538462,9.605876076923078,10.581651292307694,11.557426507692309,12.533201723076925,13.50897693846154,14.484752153846156,15.460527369230771,16.436302584615387,{"y":17.412077800000002,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.727,5.702775215384616,6.678550430769231,7.654325646153847,8.630100861538462,9.605876076923078,10.581651292307694,11.557426507692309,12.533201723076925,13.50897693846154,14.484752153846156,15.460527369230771,16.436302584615387,{"y":17.412077800000002,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.727,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.727,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >